ArticleInternational journal of molecular epidemiology and genetics2010
Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis.
Article in International journal of molecular epidemiology and genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Genetic Variation inJournal of personalized medicine · 2026Article
- Identification and Characterization of Two Aryl Sulfotransferases from Deep-Sea Marine Fungi and Their Implications in the Sulfation of Secondary Metabolites.Marine drugs · 2024Article
- Next-generation of BBQ analogues that selectively target breast cancer.Frontiers in chemistry · 2024Article
- Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.Communications biology · 2022Article
- The Roles of microRNAs in Cancer Multidrug Resistance.Cancers · 2022Review
- Estrogen Sulfotransferase is Highly Expressed in Vascular Endothelial Cells Overlying Atherosclerotic Plaques.The protein journal · 2022Article
- Interaction of Native- and Oxidized-Low-Density Lipoprotein with Human Estrogen Sulfotransferase.The protein journal · 2021Article
- Identification and targeting of selective vulnerability rendered by tamoxifen resistance.Breast cancer research : BCR · 2020Article
- MicroRNAs and cancer drug resistance: over two thousand characters in search of a role.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- SULT1E1 inhibits cell proliferation and invasion by activating PPARγ in breast cancer.Journal of Cancer · 2018Article
- Article
- RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Acta biochimica et biophysica Sinica · 2016Review
- Predictive biomarkers in precision medicine and drug development against lung cancer.Chinese journal of cancer · 2015Review
- The effects of endoxifen and other major metabolites of tamoxifen on the sulfation of estradiol catalyzed by human cytosolic sulfotransferases hSULT1E1 and hSULT1A1*1.Drug metabolism and disposition: the biological fate of chemicals · 2015Article
- Regulation of Apoptotic Endonucleases by EndoG.DNA and cell biology · 2015Article
- Pathways involved in interleukin-1β-mediated murine cardiomyocyte apoptosis.Texas Heart Institute journal · 2015Article
- Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380.Oncotarget · 2015Article
- Pharmacogenetics of SULT1A1.Pharmacogenomics · 2014Article
- Sulfotransferase genetic variation: from cancer risk to treatment response.Drug metabolism reviews · 2013Review
- Contributions of human enzymes in carcinogen metabolism.Chemical research in toxicology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Previously, we reported a strong association of the high activity SULT1A1*1 allele and overall survival of patients receiving tamoxifen therapy, indicating that sulfation of 4-hydroxytamoxifen (4-OHT) via SULT1A1 may contribute to the therapeutic efficacy of tamoxifen treatment. In most, but not all cases, sulfation is considered to be an elimination pathway; therefore we sought to define the biological mechanism by which increased sulfation of tamoxifen could provide a therapeutic benefit. We compared the antiproliferative and apoptotic responses between MCF7-SULT1A1 expressing cells and control MCF7 pcDNA3 cells when treated with 4-OHT. We observed a greater than 30% decrease in cell proliferation in MCF7-SULT1A1 expressing cells at physiological concentrations of 4-OHT, and significant cell death in SULT1A1-expressing cells treated with 2µM 4-OHT for 48 hours compared to control cells (p<0.05). Within 24 hours of drug treatment, an 80% increase in apoptosis in SULT1A1-expressing cells was apparent when compared to similarly treated cells that did not express SULT1A1. We also observed an increase in endonuclease G, the primary endonuclease expressed in ER-dependent breast cancer cells, which participates in caspaseindependent apoptosis. These data confirm that SULT1A1-mediated biotransformation of 4-OHT is important in the efficacy of 4-OHT cytotoxicity in breast tumors, and reveals a potential role for sulfated metabolites in the efficacy of tamoxifen therapy.
Indexed as
Identifiers
21537383PMC3076764W1826198237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.